Apimeds Pharmaceuticals US
APUS
6 hedge funds and large institutions have $490K invested in Apimeds Pharmaceuticals US in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.24% more ownership
Funds ownership: 0% → 0.24% (+0.24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$24.1K |
| 2 |
Goldman Sachs
New York
|
+$21.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.68K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$54 |
| 5 |
JP Morgan Chase
New York
|
+$18 |
Top Sellers
APUS Hedge Fund Activity: Q2 2025 in Review
6 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Apimeds Pharmaceuticals US (APUS) for Q2 2025, worth a combined $490K.
Buyers outnumbered sellers: 6 funds opened new APUS positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $24.1K.
- 6 institutional investors held Apimeds Pharmaceuticals US (APUS) as of Q2 2025, up from 0 in Q1 2025.
- Funds reported $490K of Apimeds Pharmaceuticals US stock for Q2 2025.
- 6 funds opened new Apimeds Pharmaceuticals US positions in Q2 2025 and 0 closed out, a net change of +6 holders.
- The largest Apimeds Pharmaceuticals US buyer in Q2 2025 was Citadel Advisors, an estimated $24.1K added.
Based on aggregated 13F filings for Q2 2025.